Does Medicare cover Wegovy & Zepbound in 2026?
The landscape is changing.
For years, Medicare beneficiaries seeking GLP-1 medications for weight management often faced significant out-of-pocket costs. Beginning July 1, 2026, a new CMS-supported program may help qualifying individuals access these medications at a substantially reduced cost.
This isn’t the same as Medicare Part D broadly covering GLP-1 medications for weight loss, but it may create a new pathway for eligible beneficiaries.
Below, we’ll explain how the program works, who may qualify, and what steps you can take next.
Historically, Medicare beneficiaries have had limited access to GLP-1 medications for weight management alone. Beginning July 1, 2026, the new CMS-supported Medicare Bridge Program will create a more affordable pathway for eligible beneficiaries, with certain GLP-1 medications available for $50 per month.
Medicare coverage, by scenario.
GLP-1 prescribed for type 2 diabetes (e.g. Ozempic, Mounjaro)
Covered under standard Medicare Part D today — and continues in 2026.
Zepbound prescribed for obstructive sleep apnea with obesity
Covered by Part D since 2025 when prescribed for moderate to severe OSA in adults with obesity — no changes in 2026.
Wegovy prescribed for MASH with advanced fibrosis
Covered by Part D since 2025 and continues in 2026.
Wegovy or Zepbound prescribed solely for chronic weight management.
Excluded by federal statute from standard Part D. Out-of-pocket cost typically $1,000–$1,400/month.
Wegovy or Zepbound for chronic weight management — on or after July 1, 2026
Covered through the new Medicare GLP-1 Bridge Program at $50/month for qualifying beneficiaries.
Coverage descriptions reflect federal Medicare guidance. Specific plan rules, prior authorization, and step therapy may apply. Individual eligibility for the Bridge Program is determined clinically.
Four things that determine eligibility.
You have Medicare
Part D enrollment (or a Medicare Advantage plan with prescription drug coverage) is required to access the Bridge Program.
Chronic weight management is the clinical reason
The medication must be prescribed specifically for chronic weight management — not for diabetes, sleep apnea, or another condition that already has standard Part D coverage.
You meet the clinical criteria
BMI thresholds and a review of medical history, current medications, and metabolic health determine appropriateness. This is the part decided in consultation with your clinician.
Expert guidance makes the process easier
The Bridge Program has specific eligibility requirements and documentation processes. Working with a clinician experienced in weight management can help you understand your options, determine whether you may qualify, and navigate the approval process with confidence.
At Storm Wellness Northwest, we help patients understand their eligibility, evaluate treatment options, and navigate the process from consultation through ongoing care.
Related guides.
Wegovy vs Zepbound for Medicare
How the two medications actually differ — mechanism, side-effect profile, trial weight loss.
GLP-1 side effects for seniors
What Medicare-age patients should watch for, and how to minimize the rough early weeks.
Who qualifies for the Bridge Program
A plain-English walkthrough of the clinical criteria and what to expect at consultation.
Find out where you stand before the July 1 launch.
A consultation with Renee Storm, APRN reviews your medical history, current medications, and metabolic health — and confirms whether the Bridge Program is a fit for you.